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ABSTRACT
Objective Troponin and high signal intensity on T2- 
weighted (highT2) cardiovascular magnetic resonance 
imaging (cMri) are both markers of myocardial injury 
in hypertrophic cardiomyopathy (hcM). The interplay 
between exercise and disease development remains 
uncertain in hcM. We sought to assess the occurrence of 
postexercise troponin rises and its determinants.
Methods Multicentre project on patients with hcM 
and mutation carriers without hypertrophy (controls). 
Participants performed a symptom limited bicycle test 
with hs- cTnT assessment pre- exercise and 6 hours 
postexercise. Pre- exercise cMri was performed in 
patients with hcM to assess measures of hypertrophy 
and myocardial injury. Depending on baseline troponin 
(< or >13 ng/l), a rise was defined as a >50% or >20% 
increase, respectively.
Results Troponin rises occurred in 18% (23/127) of 
patients with hcM and 4% (2/53) in mutation carriers 
(p=0.01). comparing patients with hcM with and 
without a postexercise troponin rise, maximum heart 
rates (157±19 vs 143±23, p=0.004) and maximal wall 
thickness (20 mm vs 17 mm, p=0.023) were higher 
in the former, as was the presence of late gadolinium 
enhancement (85% vs 57%, p=0.02). highT2 was 
seen in 65% (13/20) and 19% (15/79), respectively 
(p<0.001). highT2 was the only independent predictor 
of troponin rise (adjusted odds ratio 7.9; 95% ci 2.7 to 
23.3; p<0.001).
Conclusions Postexercise troponin rises were seen 
in about 20% of patients with hcM, almost five times 
more frequent than in mutation carriers. highT2 on cMri 
may identify a group of particularly vulnerable patients, 
supporting the concept that highT2 reflects an active 
disease state, prone to additional injury after a short 
episode of high oxygen demand.
InTROduCTIOn
In patients with hypertrophic cardiomyopathy 
(HCM), highly sensitive cardiac troponin (hs- 
cTn) is elevated in about 25%–50%.1–3 In analogy 
to other cardiac disorders, the first long- term 
follow- up data suggest that troponin is associated 
with adverse outcome in HCM.1
There is limited information about the factors 
that contribute to troponin release in this partic-
ular group of patients. Troponin concentrations 
have been related to left ventricular (LV) mass 
and the presence of imaging signs of myocardial 
injury.2–5 Importantly, it is widely appreciated that 
the hypertrophic phenotype in HCM is related to 
pathophysiological abnormalities in vasculature, 
myocardial structure and function,6 7 which may 
all contribute to the occurrence of myocardial 
ischaemia.8 9 Cardiac magnetic resonance imaging 
(CMRi) studies have correlated areas of ischaemia 
with segmental late gadolinium enhancement (LGE) 
and high signal intensity on T2- weighted imaging 
(HighT2).10–12 HighT2 has been demonstrated to 
be strongly associated with elevated troponin in 
HCM and is considered to represent an active state 
of disease.4 13
In the abovementioned context, episodes of high 
oxygen demand may pose a challenge and could 
result in additional myocardial injury. However, 
whereas studies in ischaemic heart disease and 
even in healthy individuals have already studied 
postexercise troponin release and contributing vari-
ables,14–16 data in HCM is limited.17 18
With mutation carriers without hypertrophy as a 
reference group, we aimed to assess and compare 
the proportions of patients with HCM with a 
troponin rise after a symptom limited bicycle stress 
test. In follow- up on studies that addressed troponin 
concentrations at rest and associated variables, we 
focused on clinical and CMRi variables that were 
associated with a postexercise troponin rise.
MATeRIAlS And MeTHOdS
Study population
Between 2008 and 2014, subjects were enrolled 
and participated in a Dutch multicentre study on 
CMRi and biomarkers in patients with HCM and 
mutation carriers without hypertrophy. Three 
specialised HCM outpatient clinics, that is, the 
Albert Schweitzer Hospital, Dordrecht, the Erasmus 
Medical Center, Rotterdam, and the Radboud 
University Medical Center, Nijmegen, the Neth-
erlands, collaborated in this project.4 Two groups 
were identified: (1) patients with clinical HCM, 
defined echocardiographically with a maximal 
wall thickness of ≥15 mm or ≥13 mm in case of a 
proven sarcomeric gene mutation and (2) carriers 
of a sarcomeric gene mutation, without echocardio-
graphic evidence of hypertrophy.
Exclusion criteria were cardiac hypertrophy with 
a known cause other than a sarcomeric gene muta-
tion; a history of coronary artery disease, myocardial 
infarction or stroke; a history of septal reduction 
therapy; a contraindication to perform exercise 
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testing. The study complies with the Declaration of Helsinki and 
the protocol was approved by the local ethics committee, and 
all participants gave written informed consent. Participants were 
not involved in the design or conduct or reporting or dissemina-
tion of our research.
Study protocol
At the day of the exercise test, New York Heart Association 
class, medication use, vital parameters, and a resting ECG were 
recorded and renal function was assessed prior to CMRi. After 
CMRi, participants performed a bicycle exercise test, with blood 
samples drawn at baseline and 6 hours after stress testing.
Bicycle exercise test
The exercise protocol prescribed an increase of exercise load of 
10 W every minute. During exercise blood pressure, heart rate 
and ECG were recorded every 2 min. Participants were asked to 
continue intake of heart rate reducing medication until the day 
before the test.
The test was symptom limited or terminated in case the partic-
ipant was no longer able to maintain a cycling frequency above 
40 rpm. In all other cases, the test was continued until a work-
load of 30 W above the expected maximum.
Measurement of serum cardiac troponin T
After processing, serum samples were stored at –80°C until 
further analysis. For determination of cardiac troponin T the 
hs- cTnT assay was used (Roche Diagnostics). This test has a 
limit of blank of 3 ng/L, a limit of detection of 5 ng/L and a 99th 
percentile upper reference limit of 14 ng/L. The coefficient of 
variation is reported to be less than 10% at 13 ng/L. A troponin 
level ≥14 ng/L is called elevated.
A troponin rise was defined according to the level of impreci-
sion. In case of a baseline troponin concentration <13 ng/L, an 
increase of more than 50% was required to qualify for a rise in 
troponin; for baseline values ≥13 ng/L, a >20% increase was 
defined as a rise in troponin.
CMRi
CMRi studies were performed on a 1.5T MR imaging system 
(Philips Achieva, Philips Healthcare, Best, The Netherlands; or 
Siemens Avanto, Siemens Health Care, Erlangen, Germany) and 
analysed according to a previously described protocol.4 In short, 
breath- hold triple inversion- recovery T2- weighted images with 
fat suppression were obtained to assess the presence of oedema. 
Second, steady- state free precession cine imaging was used to 
quantify LV geometry. Finally, 10 min after administration of 
0.2 mmol/kg contrast medium (Dotarem; Guerbet, Gorinchem, 
The Netherlands), the presence of LGE was assessed with 
T1- weighted inversion- recovery imaging.
Images were analysed offline with the use of Qmass software 
(Version 7.5; Medis, Leiden, The Netherlands) by two observers 
unaware of patient characteristics. LV mass was calculated by 
subtraction of endocardial from epicardial volume and multipli-
cation by 1.05 g/cm3. LV mass was normalised to body surface 
area; an increased LV mass was defined as >91 g/m2 for men and 
>69 g/m2 for women.19 A per segment analysis was performed 
automatically to assess LV maximal wall thickness (MWT) at end 
diastole. According to the American Heart Association- model, 
all 17 LV segments were visually analysed by two observers (JB, 
FG), who assessed both the presence of HighT2 and LGE, inde-
pendent of each other, and unaware of troponin results. In case 
of a discrepancy between observers, a third reader independently 
re- evaluated all images for final adjudication (HD).
Statistical analysis
Continuous variables were described as means±SDs or medians 
with IQRs, whenever appropriate. Categorical variables were 
expressed as frequencies and percentages. To compare two 
independent groups, the Student’s t or Mann Whitney U test 
were used for continuous variables, and χ² or Fisher exact test 
for dichotomous variables, whenever appropriate. The differ-
ence between median troponin concentrations pre- exercise and 
postexercise was tested with the Wilcoxon signed rank test.
Patients with clinical HCM with and without a postexercise 
troponin rise were compared. Multivariable logistic regres-
sion was performed for variables univariably associated with a 
troponin rise (p<0.10) using stepwise forward logistic regression 
(p- entry: 0.05 and p- removal: 0.10). First, a model composed of 
baseline characteristics (clinical and exercise variables) was evalu-
ated. Then, information on the pre- exercise hs- cTnT concentra-
tion was added. Finally, CMRi characteristics were included. To 
assess calibration of the models, we used the Hosmer- Lemeshow 
test. To assess the performance of each model C- statistics were 
calculated. P<0.05 indicated statistical significance. All analyses 
were performed using IBM SPSS22.
Patient and public involvement
Patients were not involved in designing of, recruitment to, or 
conduct of the study. As our study data are hypothesis generating 
with potential future clinical consequences regarding exercise in 
patients with HCM, our results will have impact on future study 
designs that might include patient- tailored exercise programmes.
ReSulTS
Pre-exercise characteristics
The final study population consists of 180 out of a total of 194 
participants: in 10, troponin test results were unavailable, in 1 
data of the exercise test was incomplete and 3 were unable to 
perform the exercise test.
In total, there are 127 patients with clinical HCM, with 93% 
in New York Heart Association class 1–2. The control group 
consists of 53 mutation carriers without hypertrophy. A muta-
tion was identified in 66% of patients with a clinical HCM. In 
81% of cases, the mutation was located in the MYBPC3 gene 
and for mutation carriers without hypertrophy in 74%.
Table 1 shows baseline characteristics of both groups. Patients 
with HCM were older and more often male than mutation 
carriers, and they more often reported symptoms and medi-
cation use. In patients with HCM, the interventricular septum 
(p<0.001) and posterior wall (p<0.001) were thicker, and the 
median left atrial diameter was larger compared with mutation 
carriers (p<0.001).
Bicycle exercise test
Table 1 shows exercise test parameters of the participants. 
Patients with HCM achieved lower absolute and relative exer-
cise loads than mutation carriers (p<0.05). Accordingly, in 
patients with HCM, the duration of exercise was shorter than 
in mutation carriers and the proportion that did not reach 80% 
of the expected load was higher (p<0.05). Patients with HCM 
had lower heart rates at maximum exercise (p<0.001) and lower 
heart rate pressure products than mutation carriers (p=0.04).
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Table 1 Baseline characteristics of patients with clinical HCM and 
mutation carriers without left ventricular hypertrophy
Variable
Clinical HCM
(n=127)
Mutation carriers
(n=53) P value
Age (years) 53±14 41±11 <0.001
Male, n (%) 76 (60) 20 (38) 0.007
Hypertension, n (%) 44 (35) 4 (8) <0.001
Implantable cardiac 
defibrillator, n (%)
10 (8) 0 (0) 0.04
History of atrial fibrillation, 
n (%)
20 (16) 0 (0) 0.002
NYHA functional class ≥2, 
n (%)
56 (44) 1 (2) <0.001
Body mass index (kg/m2) 26±3 25±4 0.05
Medication use
  Beta- blocker, n (%) 59 (47) 2 (4) <0.001
  Calcium channel blocker, 
n (%)
17 (13) 0 (0) 0.005
Echocardiography
  Interventricular septum 
thickness (mm)
16 (13–20) 10 (8–11) <0.001
  Posterior wall thickness 
(mm)
10 (10–12) 9 (7–9) <0.001
  Left atrial diameter (mm) 43 (39–49) 38 (32–40) <0.001
  LVOT gradient ≥30 mm 
Hg, n (%)
18 (14) 0 (0) 0.01
Exercise stress test
  Resting heart rate (beats/
min)
74±13 75±11 0.553
  Resting systolic blood 
pressure (mm Hg)
129±21 118±16 0.001
  Heart rate at maximum 
exercise (beats/min)
145±23 164±17 <0.001
  Maximum systolic blood 
pressure (mm Hg)
180±32 172±29 0.140
  Achieved exercise load 
(W)
140 (120–180) 160 (130–190) 0.02
  Relative achieved exercise 
load (%)
89 (74–107) 100 (89–112) 0.005
  Achieved load <80% of 
expected, n (%)
45 (35) 8 (15) 0.006
  Duration of exercise (min) 13 (9–17) 15 (12–18) 0.01
  HRPP (mm Hg*beats 
per min)
26178±6099 28214±5578 0.04
Data are described as means± SDs, medians with IQRs or numbers with 
percentages.
HCM, hypertrophic cardiomyopathy; HRPP, heart rate pressure product; LVOT, left 
ventricular outflow tract; NYHA, New York Heart Association.
Table 2 Highly sensitive cardiac troponin T results in patients with 
clinical HCM and mutation carriers without left ventricular hypertrophy
Variable
Clinical HCM
(n=127)
Mutation 
carriers
(n=53) P value
Highly sensitive cardiac troponin 
T (ng/L):
  Before exercise 8.3 (3.4–13.9) 3.0 (3.0–3.0) <0.001
  6 hours after exercise 9.9 (4.3–16.7) 3.0 (3.0–3.0) <0.001
Elevated troponin (≥14 ng/L), 
n (%):
  Before exercise 31 (24) 0 (0) <0.001
  6 hours after exercise 40 (32) 0 (0) <0.001
Postexercise cardiac troponin 
rise, n (%)
23 (18) 2 (4) 0.01
Data are described as medians with IQRs or numbers with percentages.
HCM, hypertrophic cardiomyopathy.
Postexercise troponin rise
The proportion of patients with HCM with a significant troponin 
rise 6 hours after exercise was 18% (23/127), compared with 4% 
(2/53) in mutation carriers (p=0.01). In patients with HCM, 
the pre- exercise median troponin concentration was 8.3 ng/L vs 
9.9 ng/L postexercise (p<0.001). Pre- exercise levels ≥14 ng/L 
were seen in 24%, and postexercise, this was observed in 32% 
(table 2). Among mutation carriers, there were no individuals 
with a hs- cTnT ≥14 ng/L, neither before nor after exercise.
Contributors to postexercise troponin rise in HCM
Table 3 displays clinical, biomarker and imaging characteristics in 
association with a troponin rise.
Clinical
Patients with clinical HCM with a postexercise troponin rise had 
higher pre- exercise heart rates (p=0.03), and higher maximum 
heart rates (p=0.004).
Biomarker
The percentage of patients with HCM with a pre- exercise troponin 
level ≥14 ng/L tended to be higher than observed in patients 
without a rise (p=0.07).
Imaging
In 109 of the 127 patients with HCM, CMRi was performed. 
Median MWT was 20 mm (15-23 mm) in patients with a rise, 
and 17 mm (14–20 mm) in patients without (p=0.023). LGE 
was present in 85% (17/20) of patients with and in 57% (51/89) 
without a rise (p=0.02). HighT2 was seen in 65% (13/20) and 
19% (15/79) (p<0.001), respectively. A typical example of a 
patient with signs of HighT2 is shown in figure 1. Of the 28 
patients with evidence of HighT2, a postexercise troponin rise 
was seen in 46% (13/28), which was more than four times more 
often than in patients without HighT2 (9.9%; 7/71). In figure 2, 
pre- exercise and postexercise troponin levels are displayed 
according to the number of myocardial segments with HighT2. 
There were more patients with a postexercise troponin rise 
in the groups with 1 or 2, and 3 or more HighT2 myocardial 
segments as compared with patients with HCM without signs of 
HighT2 (p<0.001).
In multivariable logistic regression analysis, only the presence 
of HighT2 was independently associated with a postexercise 
troponin rise (OR 7.9; 95% CI 2.7 to 23.3; p<0.001) (table 4).
dISCuSSIOn
This study is a report on postexercise troponin release in the largest 
HCM population to date and is the first to describe its determinants. 
A postexercise troponin rise occurred in about 20% of patients 
with HCM, which was almost five times more frequent than in 
mutation carriers. According to our expectation, we observed a 
clear association with heart rate and maximal wall thickness, which 
fits into the classical concept that increased oxygen demand may 
elicit postexercise injury in the setting of hypertrophy. However, 
our CMR findings provide important new insights in the under-
lying pathophysiology. Independent of other factors, such as LV 
mass, HighT2 identified a specific group of patients with HCM 
especially vulnerable for further injury. Appreciating that HighT2 
has been suggested to reflect an active disease state of HCM, the 
present study gives rise to the hypothesis that (repetitive) episodes 
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Table 3 Univariable associations with a postexercise troponin rise: 
clinical, biomarker and MRI characteristics
Variable
Clinical HCM with 
troponin rise
(n=23)
Clinical HCM 
without troponin 
rise (n=104) P value
Age (years) 51±15 54±14 0.405
Male, n (%) 14 (61) 62 (60) 0.912
Hypertension, n (%) 7 (30) 37 (36) 0.639
NYHA functional class ≥2, 
n (%)
12 (52) 44 (42) 0.388
Body mass index (kg/m2) 26±4 26±3 0.728
Medication use       
Beta- blocker, n (%) 8 (35) 51 (49) 0.215
Calcium channel blocker, 
n (%)
2 (9) 15 (14) 0.736
Mutation type (n=115) (n=21) (n=94)   
No mutation found, n (%) 9 (43) 38 (40) 0.121*
MYBPC3, n (%) 11 (52) 44 (47)
MYH7, n (%) 0 (0) 10 (11)
other, n (%) 1 (5) 2 (2)
Exercise stress test       
Resting heart rate (beats/
min)
79±15 73±12 0.03
Heart rate at maximum 
exercise (beats/min)
157±19 143±23 0.004
Resting systolic blood 
pressure (mm Hg)
128±18 129±22 0.860
Maximum systolic blood 
pressure (mm Hg)
179±30 180±32 0.959
Achieved exercise load (W) 170 (120-200) 140 (113-178) 0.125
Relative achieved exercise 
load (in %)
93±20 90±21 0.579
Achieved load <80% of 
expected, n (%)
7 (30) 38 (37) 0.580
Duration of exercise (min) 15 (10-18) 13 (8-17) 0.223
HRPP (mm Hg*beats per 
min)
28119±4889 25740±6278 0.09
Highly sensitive cardiac 
troponin T (ng/L)
8.8 (4.8–19.9) 8.2 (3.3–13.1) 0.195
Elevated troponin 
(≥14 ng/L), n (%)
9 (39) 22 (21) 0.07
CMRi (n=109) (n=20) (n=89)   
LV mass indexed by BSA 
(g/m2)
72 (53-112) 61 (52-75) 0.112
Increased LV mass, n (%)† 7 (35) 16 (18) 0.127
Maximal wall thickness 
(mm)
20 (15-23) 17 (14-20) 0.02
Presence of LGE, n (%) 17 (85) 51 (57) 0.02
Presence of HighT2, n (%) 13 (65) 15 (19) <0.001
Data are described as means±SDs, medians with IQRs or numbers with percentages.
*No significant differences among subgroups.
†Defined as >91 g/m2 for men, and >69 g/m2 for women.19
BSA, body surface area; CMR, cardiac magnetic resonance; HCM, hypertrophic 
cardiomyopathy; HighT2, elevated signal intensity on T2- weighted images; HRPP, 
heart rate pressure product; LGE, late gadolinium enhancement; LV, left ventricular; 
NYHA, New York Heart Association.
Figure 1 Example of a patient with elevated signal intensity on T2- 
weighted imaging. Panel A: T2- weighted image; panel B: cine image; 
panel C: T1- weighted image showing late gadolinium enhancement in 
the hypertrophied part of the basal septum.
of high oxygen demand may result in ‘bouts’ of troponin release. 
In the context that the impact of exercise in HCM is currently 
unknown, our findings may stimulate future research towards 
more individualised recommendations regarding exercise.
Troponin release in HCM
With regard to troponin status under resting conditions, 
various mechanisms have been implicated to explain detectable 
concentrations in different sets of populations. Whereas in 
HCM some of these mechanisms may be disease- specific, there 
will also be an overlap with other patient populations, and 
even with healthy individuals.20–22 In the community dwelling 
population, there is a clear association between LV mass and the 
observed baseline hs- cTnT concentration.22 Also, in HCM, there 
is an association between measures of LV hypertrophy and base-
line cTnT.4 In HCM, however, cardiac hypertrophy is accom-
panied by impaired myocardial structure and function, with 
myocyte disarray and inefficient energy utilisation. In addition, 
perfusion abnormalities and impaired microvascular function 
are also part of the clinical picture.23 These characteristics are 
additional conditions that may contribute to troponin release, 
which may become especially apparent in situations of high 
oxygen demand, such as exercise. Appreciating that postexercise 
troponin rises are also observed in healthy individuals,16 a group 
of mutation carriers without hypertrophy served as a reference. 
Exercise intensity was markedly higher in this control group 
and can be considered a well- known determinant of postexer-
cise troponin.16 Despite the difference in exercise intensity, we 
observed a fivefold higher rate of postexercise troponin rises 
in the patients with HCM, which suggests that the underlying 
pathophysiology specific to the HCM phenotype is the main 
contributor to exercise- induced troponin release.18
Imaging studies in HCM
In addition to the above- mentioned aspects, several imaging 
studies have provided more detailed evidence on the processes 
observed during stress/exercise in HCM. First, stress imaging 
studies demonstrated that although hypoperfusion is most 
often seen in areas of hypertrophy, it also occurs in other 
myocardial areas, both at rest and during stress, which impli-
cates another mechanism than increased oxygen demand due 
to hypertrophy.10–12 Second, a previous study on exercise in 
HCM addressed the issue of inefficient energy utilisation and 
demonstrated that exercise worsened the energy deficit in these 
patients, independent of hypertrophy and fibrosis.24 This aspect 
may have contributed to our observation that a troponin rise 
after exercise is not confined to patients with the highest LV 
mass and/or wall thickness.
Interestingly, in multivariable analysis, HighT2 was found to 
be the only variable associated with a postexercise troponin rise. 
Considering that 80% of patients did not show biomarker signs 
of postexercise injury, higher oxygen demand by itself is not the 
key driver of myocardial injury after exercise. The underlying 
state of cardiac disease seems an important predisposing factor 
to develop a postexercise troponin rise.
Under resting conditions, there is a strong association between 
hs- cTnT and HighT2. HighT2 is considered to represent an active 
state of disease, with recently sustained myocardial injury.4 13 With 
Protected by copyright.
 o
n
 February 27, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2019-315818 on 30 January 2020. Downloaded from 
5cramer ge, et al. Heart 2020;0:1–7. doi:10.1136/heartjnl-2019-315818
Heart failure and cardiomyopathies
Key messages
What is already known on this subject?
 ► In hypertrophic cardiomyopathy (HCM), troponin and high 
signal intensity on T2- weighted (HighT2) cardiovascular 
magnetic resonance imaging (CMRi) are both markers of 
myocardial injury. A resting troponin elevation is seen in 
about 25%–50% of patients, especially in case of HighT2 
(oedema). The interplay between exercise in HCM and 
development of disease remains uncertain. An increase in 
troponin after exercise has been reported, but how often this 
occurs, and its potential determinants are unknown.
What might this study add?
 ► A postexercise troponin rise was observed in about one 
out of five patients with HCM, five times more frequent 
than in mutation carriers without the phenotype. In line 
with the classical concept of hypertrophy and increased 
oxygen demand, heart rate and maximal wall thickness were 
univariable determinants. The only independent association 
was found for HighT2. This shows that exercise per se does 
not cause injury in the majority of patients with HCM, and 
that CMRi may identify a particularly vulnerable subgroup.
How might this impact on clinical practice?
 ► These data provide the first indication that the injury- 
response to exercise differs among patients with HCM and 
that patients with a more active state of disease (HighT2 on 
CMRi) are more vulnerable. These findings may stimulate 
future research that could contribute to more individualised 
recommendations with regard to exercise (intensity) in HCM.
Figure 2 Highly sensitive cardiac troponin T values according to number of segments with HighT2 0 segments: 9.9% of patients with HCM with a 
postexercise rise; 1–2 segments: 50%; 3 or more segments: 43%; p value for difference between groups<0.001. HighT2, elevated signal intensity on 
T2- weighted imaging.
Table 4 Postexercise troponin rise in HCM: multivariable logistic 
regression
Variables with an independent 
association: Adjusted OR (95% CI) P value
(a) Model-1—clinical variables*
  Heart rate at maximum exercise 1.4 (1.1 to 1.7)† 0.007
(b) Model-2—clinical & biomarker 
information*
  Heart rate at maximum exercise 1.4 (1.1 to 1.7)† 0.007
(c) Model-3—clinical, biomarker & CMR 
information‡
  HighT2 7.9 (2.7 to 23.3) <0.001
(a) Model-1: evaluated variables are: resting heart rate; heart rate at maximum 
exercise; heart rate pressure product; (b) Model-2: evaluated variables are: model-
1+pre- exercise cardiac troponin T level ≥14 ng/L; (c) Model-3: evaluated variables 
are: model-2+maximal wall thickness; presence of late gadolinium enhancement; 
presence of elevated signal intensity on T2- weighted imaging.
*Performance of model-1 and model-2: C- statistic (95% CI) 0.69 (0.59–0.80).
†OR per 10 beats/min increase.
‡Performance of model-3: C- statistic (95% CI) 0.73 (0.60–0.86).
CMR, cardiac magnetic resonance; HighT2, elevated signal intensity on T2- weighted 
imaging.
CMRi performed prior to the bicycle test, our findings support the 
concept that patients with HCM with signs of oedema represent 
a group with active disease, vulnerable to new injury. As HCM 
is highly heterogeneous, the occurrence of postexercise troponin 
rises in patients with HCM with HighT2 is subject to variation 
among individuals. In view of this, HighT2 remains present for a 
longer period of time, and repeated exercise with different inten-
sities will cause troponin releases on some, but not all occasions.
These findings may contribute to further improve the char-
acterisation of different disease states with the use of CMRi, as 
previously suggested by others.11
Implications
This study provides insights that may contribute to further inves-
tigate the role of exercise in HCM. At present, available infor-
mation is limited and guideline recommendations lack high- level 
scientific support.25 Several observations have recently made 
experts to suggest that the risks of exercise are low.26–28 However, 
the associated risks and benefits in this patient population are 
uncertain, and guidance to differentiate for whom exercise may 
be beneficial, or potentially harmful, is lacking.25
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Importantly, whereas about 80% of patients did not show a 
postexercise rise in troponin, HighT2 could identify a subset of 
patients who were vulnerable to additional injury in almost 50%. 
The clinical potential of this differentiation requires further 
follow- up, which is supported by observations that HighT2 has 
been linked to a higher risk of non- sustained ventricular tachy-
cardia and syncope.29 30 Ultimately, this distinction has the poten-
tial to contribute to more individualised recommendations.
First, however, additional information is needed with regard 
to the clinical meaning of a postexercise troponin rise, in terms 
of progression of disease and prognosis. In this regard the asso-
ciations that we found are first- time findings that need to be 
substantiated in larger- sized cohorts with follow- up CMRi 
to assess a potential causal relationship between postexercise 
troponin rises and imaging signs of progressive myocardial 
disease. Therefore, further research is warranted to assess the 
association with outcomes such as, for example, extension of 
LGE, LV deterioration and clinical endpoints like heart failure 
and (arrhythmic) death.
In case of a demonstrated association with adverse outcome, 
this could pave the way for future research. As far as potential 
interventions are concerned, we previously reported in a pilot 
study that postexercise release of troponin in HCM could be 
blunted with the use of a beta- blocker.17 Future developments 
may include defining individualised exercise thresholds based 
on intensities that result in postexercise injury. Appreciating 
the current gaps in knowledge for an every- day issue like exer-
cise, future initiatives to more personalised, informed decision 
making are eagerly awaited.
limitations
Although this is the largest prospective, controlled study 
addressing the impact of exercise on troponin release in HCM, 
the sample size is still modest and associations of other variables 
with a postexercise troponin rise may have gone undetected. As 
an example, differentiation according to mutation type could 
prove of interest as some mutations might do worse than others. 
Second, we excluded patients with a history of cardiovascular 
disease and/or septal reduction therapy; thus, findings cannot be 
generalised to the entire HCM population.
In retrospect, a more extensive CMRi protocol including 
adenosine, T1 and T2 mapping would have provided more elab-
orate tissue characterisation, which might have resulted in addi-
tional insights. However, at the time of study design, the latter 
two techniques were not available.
With our current knowledge on release patterns of hs- cTnT 
after exercise, the timing of blood samples 6 hours postexercise 
may have been rather late. However, at the time of study design, 
data on troponin, exercise and HCM was limited.
COnCluSIOn
In patients with HCM, a postexercise troponin rise is observed 
in about 20%, almost five times more frequent than in muta-
tion carriers without hypertrophy. In the latter, exercise was well 
tolerated with only a few cases showing a limited rise in the level 
of troponin. In patients with clinical HCM, maximal wall thick-
ness and heart rate were associated with the occurrence of a rise, 
but the only independent association was found for the presence 
of HighT2 at CMRi prior to exercise. These findings give rise to 
the hypothesis that in HCM, episodes of high oxygen demand 
may elicit additional myocardial injury particularly in case of an 
active state of disease.
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